---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296244423.md"
description: "Scribe Therapeutics shares are trading higher after multiple analyst firms initiated coverage on the stock with their respective ratings and price targets."
datetime: "2026-08-18T14:33:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296244423.md)
  - [en](https://longbridge.com/en/news/296244423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296244423.md)
generator: "portal-rs"
---

# 

Scribe Therapeutics shares are trading higher after multiple analyst firms initiated coverage on the stock with their respective ratings and price targets.

### Related Stocks

- [SCTX.US](https://longbridge.com/en/quote/SCTX.US.md)

## Related News & Research

- [SCTX: CRISPR-driven therapies show promise for durable cardiovascular disease prevention and treatment](https://longbridge.com/en/news/297828691.md)
- [OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake](https://longbridge.com/en/news/294271636.md)
- [Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisition](https://longbridge.com/en/news/293991409.md)
- [Scribe secures $129M in a rare gene editing IPO](https://longbridge.com/en/news/293954820.md)
- [Scribe Therapeutics Inc. (NASDAQ:SCTX) Receives Average Rating of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/297896586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**